Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Combination therapy with angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) decreases proteinuria; however, its safety and effect on the progression of kidney disease are uncertain. Methods We provided losartan (at a dose of 100 mg per day) to patients with type 2 diabetes, a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 300, and an estimated glomerular filtration rate (GFR) of 30.0 to 89.9 ml per minute per 1.73 m(2) of body-surface area and then randomly assigned them to receive lisinopril (at a dose of 10 to 40 mg per day) or placebo. The primary end point was the first occurrence of a change in the estimated GFR (a decline of ≥ 30 ml per minute per 1.73 m(2) if the initial estimated GFR was ≥ 60 ml per minute per 1.73 m(2) or a decline of ≥ 50% if the initial estimated GFR was <60 ml per minute per 1.73 m(2)), end-stage renal disease (ESRD), or death. The secondary renal end point was the first occurrence of a decline in the estimated GFR or ESRD. Safety outcomes included mortality, hyperkalemia, and acute kidney injury. Results The study was stopped early owing to safety concerns. Among 1448 randomly assigned patients with a median follow-up of 2.2 years, there were 152 primary end-point events in the monotherapy group and 132 in the combination-therapy group (hazard ratio with combination therapy, 0.88; 95% confidence interval [CI], 0.70 to 1.12; P=0.30). A trend toward a benefit from combination therapy with respect to the secondary end point (hazard ratio, 0.78; 95% CI, 0.58 to 1.05; P=0.10) decreased with time (P=0.02 for nonproportionality). There was no benefit with respect to mortality (hazard ratio for death, 1.04; 95% CI, 0.73 to 1.49; P=0.75) or cardiovascular events. Combination therapy increased the risk of hyperkalemia (6.3 events per 100 person-years, vs. 2.6 events per 100 person-years with monotherapy; P<0.001) and acute kidney injury (12.2 vs. 6.7 events per 100 person-years, P<0.001). Conclusions Combination therapy with an ACE inhibitor and an ARB was associated with an increased risk of adverse events among patients with diabetic nephropathy. (Funded by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development; VA NEPHRON-D ClinicalTrials.gov number, NCT00555217.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given that diastolic heart disease develops early in T2D and the renin-angiotensin-aldosterone system (RAAS) plays a critical role in the pathophysiology of HF, the use of an ACE inhibitor or ARBs could be considered early in the treatment of hypertension, before the diagnosis of HF.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [260]
In the citing paper
“Given that diastolic heart disease develops early in T2D and the renin-angiotensin-aldosterone system (RAAS) plays a critical role in the pathophysiology of HF, the use of an ACE inhibitor or ARBs could be considered early in the treatment of hypertension, before the diagnosis of HF.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [260]
In the citing paper
“Two clinical trials studied the combinations of ACE inhibitors and ARBs and found no benefits on CVD or CKD, and the medication combination had higher adverse event rates (hyperkalemia and/or AKI) (87,88).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [88]
In the citing paper
“Long-term outcome trials in patients with diabetes and CKD demonstrated no kidney or cardiovascular bene fi t of RAS blockade with combined therapy to block the RAS versus the single use of RAS inhibitors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [85]
In the citing paper
“However, combination therapy was associated with a higher rate of hyperkalemia and AKI, 85,86”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [85]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Mann, J. F., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., Wang, X., Maggioni, A., Budaj, A., Chaithiraphan, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61236-2 · Cited by 1,589
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Clinical Physiology of Acid-Base and Electrolyte Disorders
(1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-2-176_8 · Cited by 1,156
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00653.x · Cited by 975
Ruggenenti, P., Perna, A., Gherardi, G., Garini, G., Zoccali, C., Salvadori, M., Scolari, F., Schena, F. P., & Remuzzi, G. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10363-x · Cited by 910
Research works printed but not linked: 2
- National Kidney Foundation, 2002, Am J Kidney Dis, 30, S1
- International Conference on Harmonisation, 1995, Fed Regist, 60, 11284
Cited by
Items 701–800 of 1,001
Diabetic kidney disease in primary care
Fong, J., Tsang, L. P. M., Kwek, J. L., & Guo, W. (2020) · Singapore Medical Journal · doi:10.11622/smedj.2020127 · Cited by 9
Management of Hyperkalemia in Heart Failure
Altay, H., Çavuşoğlu, Y., Çelik, A., Demir, Ş., Adana Devlet Hastanesi, K. K., Kılıçarslan, B., Tepecik Egitim ve Arastirma Hastanesi, K. K., Nalbantgil, S., Temizhan, A., Tokgöz, B., et al. (2021) · Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology · doi:10.5543/tkda.2021.s1 · Cited by 8
Cellular and molecular aspects of diabetic nephropathy; the role of VEGF-A
Carranza, K., Verón, D., Cercado, A. G., Bautista, N., Pozo, W., Tufró, A., & Verón, D. (2015) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2015.05.003 · Cited by 8
Säemann, M. D., Cejka, D., Schmaldienst, S., Rosenkranz, A. R., & Mayer, G. J. (2022) · Wiener klinische Wochenschrift · doi:10.1007/s00508-022-02096-x · Cited by 10
Kiernan, E. A., Hu, D. G., Thiessen‐Philbrook, H., Ix, J. H., Bonventre, J. V., Coca, S. G., Moledina, D. G., Fried, L. F., Shlipak, M. G., & Parikh, C. R. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.07.012 · Cited by 8
Self-citationZimering, M. B., Zhang, J. H., Guarino, P., Emanuele, N., McCullough, P. A., & Fried, L. F. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00128 · Cited by 10
Self-citationRastogi, A., Arman, F., & Alipourfetrati, S. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0663-4 · Cited by 8
Clinical Trials in Autosomal Dominant Polycystic Kidney Disease
Yu, A. S. L., Ters, M. E., & Winklhofer, F. T. (2015) · Codon Publications eBooks · doi:10.15586/codon.pkd.2015.ch6 · Cited by 10
Elrggal, M. E., Ahmed, S. M. S., & Nahas, M. E. (2016) · Saudi Journal of Kidney Diseases and Transplantation · doi:10.4103/1319-2442.194583 · Cited by 8
Antihypertensive Treatment in Diabetic Kidney Disease: The Need for a Patient-Centered Approach
Bonino, B., Leoncini, G., Cosmo, S. D., Greco, E., Russo, G. T., Giandalia, A., Viazzi, F. C., & Pontremoli, R. (2019) · Medicina · doi:10.3390/medicina55070382 · Cited by 8
Thomas, G., & Rahman, M. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.14610920 · Cited by 8
Zhao, M., Qu, H., Wang, R., Yu, Y., Chang, M., Ma, S., Zhang, H., Wang, Y., & Zhang, Y. (2021) · Medicine · doi:10.1097/md.0000000000026544 · Cited by 9
Blood pressure management in patients with type 2 diabetes mellitus
Kai, H. (2017) · Hypertension Research · doi:10.1038/hr.2017.55 · Cited by 8
Personalized medicine in diabetic kidney disease
Idzerda, N. M. A., Pena, M. J., & Heerspink, H. J. L. (2018) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000447 · Cited by 8
Slowing Progression of Chronic Kidney Disease
Drawz, P. E., Hostetter, T. H., & Rosenberg, M. E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815876-0.00057-7 · Cited by 10
Staying up to date with the JNC 8 hypertension guideline
Feldman, H. A., Zuber, K., & Davis, J. S. (2014) · JAAPA · doi:10.1097/01.jaa.0000451865.17954.9b · Cited by 8
Ku, E., Copeland, T. P., McCulloch, C. E., Abebe, K. Z., Chonchol, M., Perrone, R. D., Rahbari-Oskoui, F. F., Yu, A. S. L., Steinman, T. I., Chapman, A. B., et al. (2024) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.06.020 · Cited by 7
Yu, D., Li, J., Cheng, Y., Wang, H., Ma, X., Ding, T., & Zhu, Z. (2025) · PLoS ONE · doi:10.1371/journal.pone.0313309 · Cited by 9
El-Haddad, B. N., Reule, S. A., & Drawz, P. E. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0640-3 · Cited by 7
Brunström, M., & Carlberg, B. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001663 · Cited by 8
Optimizing Renin-Angiotensin System Inhibitor Use in CKD
Chang, T. I., & Lerma, E. V. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12950921 · Cited by 8
Antisense Oligonucleotide: A Potential Therapeutic Intervention for Chronic Kidney Disease
Li, Y., Tan, Y., Zhang, R., Wang, T., Na, N., Zheng, T., Veedu, R. N., & Chen, S. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2010004 · Cited by 7
Rastogi, A., & Weir, M. R. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108515 · Cited by 8
Li, Y., Gao, S., Guo, Z., Chen, Z., Wei, Y., Li, Y., Ba, Y., Liu, Z., & Bao, H. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150263 · Cited by 7
Schievink, B., Mol, P. G. M., & Heerspink, H. J. L. (2015) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000159 · Cited by 8
Ito, S., Kagawa, T., Saiki, T., Shimizu, K., Kuroda, S., Sano, Y., & Umeda, Y. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07720618 · Cited by 7
Recomendaciones para el manejo del riesgo cardiorrenal en el paciente con diabetes mellitus tipo 2
Castillo, G. A., Aroca, G., Buelvas, J., Buitrago, A. F., Carballo-Zárate, V., Cárdenas, J. M., Gómez, E. A., Fériz, K., Lopera, J. M., Enrique Melgarejo, R., et al. (2020) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2020.07.005 · Cited by 12
Liang, J., He, J., Gao, Y., & Zhu, Z. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/1025053 · Cited by 7
Hypertension Management in Patients with Chronic Kidney Disease in the Post-SPRINT Era
Jung, H. H. (2021) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2021.19.2.19 · Cited by 8
Non-interventional management of resistant hypertension
Doumas, M. N., Tsioufis, C., Faselis, C., Lazaridis, A., Grassos, H., & Papademetriou, V. (2014) · World Journal of Cardiology · doi:10.4330/wjc.v6.i10.1080 · Cited by 7
Drug development: how academia, industry and authorities interact
Garattini, S. K., & Perico, N. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.133 · Cited by 8
Fox, C. H., Neuhaus, K., & Vassalotti, J. (2013) · OA Nephrology · doi:10.13172/2053-0293-1-3-1027 · Cited by 10
CCR2 inhibition: a panacea for diabetic kidney disease?
Weir, M. R. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00286-7 · Cited by 7
Chan, E. S., Hemmelgarn, B. R., Klarenbach, S. W., Manns, B., Mustafa, R. A., NESRALLAH, G. E., & McQuillan, R. (2017) · Canadian Journal of Kidney Health and Disease · doi:10.1177/2054358117695570 · Cited by 8
Awad, M. H., Ulbrich, T. R., Furdich, K., Schneider, S. R., & Gothard, M. D. (2018) · Journal of Pharmacy Technology · doi:10.1177/8755122518818826 · Cited by 7
(2020) · Diabetes : current and future developments · doi:10.2174/97898114220031200101 · Cited by 7
Dual renin–angiotensin system blockade and outcome benefits in hypertension: a narrative review
Mann, J. F. E., & Böhm, M. (2015) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000173 · Cited by 7
Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease
Feng, Y., & Fu, P. (2015) · Chinese Medical Journal · doi:10.4103/0366-6999.172599 · Cited by 9
Yuan, X., Tang, W., Lin, C., He, H., & Li, L. (2023) · Acta Biochimica Polonica · doi:10.18388/abp.2020_6778 · Cited by 9
Zhu, D., Judge, P. K., Staplin, N., Haynes, R., & Herrington, W. G. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae210 · Cited by 7
Liew, A., Bavanandan, S., Hao, C., Lim, S. K., Prasad, N., Sahay, M., Susantitaphong, P., Roberts, V., Wijewickrama, E. S., Wong, M. G., et al. (2025) · Nephrology · doi:10.1111/nep.70030 · Cited by 7
Treatment Strategies to Prevent Renal Damage in Hypertensive Children
Czarniak, P., & Zurowska, A. M. (2014) · Current Hypertension Reports · doi:10.1007/s11906-014-0423-2 · Cited by 7
Complicaciones crónicas de la diabetes mellitus: visión práctica para el médico de atención primaria
Páez, J. A., Triana, J., Ruiz, M. Á., Masmela, K. M., Parada, Y. A., Peña, C. A., Perdomo, C. M., Quintanilla, R. A., Ramírez, A. F., & Villamil, E. S. (2016) · Revista Cuarzo · doi:10.26752/cuarzo.v22.n1.144 · Cited by 6
Veitch, M. R., Thai, K., Zhang, Y., Desjardins, J., Kabir, G., Connelly, K. A., & Gilbert, R. E. (2020) · Nephrology · doi:10.1111/nep.13828 · Cited by 6
Complexity and Management of Chronic Kidney Disease
Wandile, P. M. (2023) · Open Journal of Nephrology · doi:10.4236/ojneph.2023.133027 · Cited by 7
Renin Angiotensin Aldosterone System Blockers
Shibata, S., & Fujita, T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00022-0 · Cited by 7
Uchida, H. A., Wada, J., Motoki, H., Kuwahara, K., Kario, K., Katsuya, T., Shimosawa, T., Tsujita, K., Suzuki, S., Suedomi, T., et al. (2025) · Hypertension Research · doi:10.1038/s41440-025-02259-z · Cited by 8
Optimal targets for blood pressure control in chronic kidney disease: the debate continues
Knight, J. F., Wong, M. G., & Perkovic, V. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000060 · Cited by 6
Improving Care of Patients With CKD: The 2015 National Kidney Foundation Presidential Address
Berns, J. S. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.07.012 · Cited by 6
Should We Still Believe in Randomized Controlled Trials in Nephrology?
Cortinovis, M., Perico, N., & Remuzzi, G. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000450618 · Cited by 6
Pathophysiology of Diabetic Nephropathy
Herman‐Edelstein, M., & Doi, S. Q. (2016) · Springer eBooks · doi:10.1007/978-3-319-43359-2_4 · Cited by 7
Pollock, C. A., Żuk, A., Anders, H., Ganji, M. R., Johnson, D. W., Kasiske, B. L., Langham, R. G., Pecoits‐Filho, R., Remuzzi, G., Rossert, J., et al. (2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.07.008 · Cited by 7
Nitta, K., Nagai, T., Mizunuma, Y., Kitada, M., Nakagawa, A., Sakurai, M., Toyoda, M., Haneda, M., Kanasaki, K., & Koya, D. (2019) · Clinical and Experimental Nephrology · doi:10.1007/s10157-019-01733-6 · Cited by 6
Renin Angiotensin Aldosterone System Inhibitors in Chronic Kidney Disease: A Difficult Equation
Sanidas, E. A., Papadopoulos, D., Chatzis, M., Velliou, M., & Barbetseas, J. D. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00467-9 · Cited by 7
CCL24 Protects Renal Function by Controlling Inflammation in Podocytes
Wang, Y., Wu, X., Geng, M., Ding, J., Lv, K., Du, H., Ding, J., Pei, W., Hu, X., Gu, J., et al. (2021) · Disease Markers · doi:10.1155/2021/8837825 · Cited by 6
Maarouf, O. H. (2021) · Springer eBooks · doi:10.1007/978-3-030-83082-3_6 · Cited by 6
Nephroprotection by dual RAS blockade—a welcome back
Ruggenenti, P. L., & Remuzzi, G. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.132 · Cited by 6
A Paradigm Shift for the Concept of Diabetic Nephropathy
Gohda, T., & Tomino, Y. (2014) · Juntendō Igaku/Juntendo igaku · doi:10.14789/jmj.60.293 · Cited by 6
Testing for Albuminuria in 2014
McFarlane, P. A. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.07.221 · Cited by 6
Nakamoto, H., Fujita, T., Origasa, H., Isono, M., Kurumatani, H., Okada, K., Kanoh, H., Kiriyama, T., & Yamada, S. (2014) · BMC Nephrology · doi:10.1186/1471-2369-15-153 · Cited by 6
Comprehensive Care for People With Diabetic Kidney Disease
Jain, K., & Mottl, A. K. (2015) · Diabetes Spectrum · doi:10.2337/diaspect.28.3.187 · Cited by 7
NICE guidance on type 2 diabetes in adults – what's new?
Morris, D. (2016) · Independent Nurse · doi:10.12968/indn.2016.3.17 · Cited by 6
Capítulo 5 - Decisão e Metas Terapêuticas
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Figueiredo, C., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160155 · Cited by 10
The impact of antihypertensives on kidney disease
Márquez, D. F., Ruiz‐Hurtado, G., & Ruilope, L. M. (2017) · F1000Research · doi:10.12688/f1000research.9916.1 · Cited by 7
The renin–angiotensin–aldosterone system update: full-court press
PROVENZANO, A. M., & Sparks, M. A. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz123 · Cited by 6
New Molecules for Treating Resistant Hypertension: a Clinical Perspective
Azzam, O., Kiuchi, M. G., Ho, J. K., Matthews, V. B., Lugo‐Gavidia, L. M., Nolde, J. M., Carnagarin, R., & Schlaich, M. P. (2019) · Current Hypertension Reports · doi:10.1007/s11906-019-0978-z · Cited by 6
Therapeutic effect of Chinese prescription Kangen-karyu in patients with diabetic nephropathy
Park, C. H., Hiratani, K., Natazuka, T., & Yokozawa, T. (2020) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2020.01013 · Cited by 6
Rossing, P. R. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab243 · Cited by 8
Jonaitienė, N., Ramantauskaitė, G., & Laukaitienė, J. (2021) · Heart Views · doi:10.4103/heartviews.heartviews_211_20 · Cited by 10
The spectrum of nephrocutaneous diseases and associations
Wofford, J., Fenves, A. Z., Jackson, J. M., Kimball, A. B., & Menter, A. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.05.039 · Cited by 6
Yokoyama, Y., Hanai, K., Mori, T., Yamamoto, Y., Yoshida, N., Murata, H., Shinozaki, T., & Babazono, T. (2023) · Clinical and Experimental Nephrology · doi:10.1007/s10157-023-02328-y · Cited by 5
Pan, H., Yang, P.-L., Lin, C.-H., Chi, C.-Y., Lu, C., Lai, T., Yeh, C., Chen, M. Y., Wang, T., Kao, H., et al. (2024) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2024.09.023 · Cited by 5
Huang, Q., Chen, A., Tang, S., Leng, Y., Zhang, Y., Wan, B., Han, Y., Luo, Y., & Xie, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1444808 · Cited by 5
Carlesso, R., Cappellari, Y. L. R., Boeff, D. D., Pereira, A. C. C., Rusch, E. S., Claudino, T. D. S., Ritter, M. R., & Konrath, E. L. (2025) · Plants · doi:10.3390/plants14050648 · Cited by 5
Fong, J. M. N., Sia, C., & See, K. C. (2025) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2025-012 · Cited by 5
Complete inhibition of the renin–angiotensin–aldosterone system; where do we stand?
Chen, S. S., Seliger, S. L., & Fried, L. F. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000043 · Cited by 7
Self-citationRETROSPECTIVE STUDY ON ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS TREATMENT
Maghiar, F. (2020) · FARMACIA · doi:10.31925/farmacia.2020.1.13 · Cited by 5
The Renin–Angiotensin–Aldosterone System and the Kidney
Ko, B. S., & Bakris, G. L. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-803247-3.00002-7 · Cited by 5
Dual RAAS blockade for kidney failure: hope for the future
Jafar, T. H., & Assam, P. N. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60132-5 · Cited by 5
The spectrum of nephrocutaneous diseases and associations
Pascoe, V. L., Fenves, A. Z., Wofford, J., Jackson, J. M., Menter, A., & Kimball, A. B. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.05.042 · Cited by 6
Noh, Y., Lee, J., Shin, S., Park, I., Bae, S. K., Oh, E., & Lee, S. (2017) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-017-0578-4 · Cited by 5
Shahi, N., & Tobe, S. W. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.052 · Cited by 7
Treating diabetic complications; from large randomized clinical trials to precision medicine
Heerspink, H. J. L., & de Zeeuw, D. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13418 · Cited by 5
Emerging paradigms of treating diabetic nephropathy
Chang, Y., Moradi, H., & Kalantar‐Zadeh, K. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30304-8 · Cited by 5
Wang, X., Hai, Z., Wu, X., Xi, G., & Zhou, S. (2018) · Medical Science Monitor · doi:10.12659/msm.907412 · Cited by 5
"Prevalence of Hypertension Among Doctors and Risk Factors in Al-Thawra Hospital, Sanaa in 2019"
Thabit, H. A. (2021) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2021.36.005838 · Cited by 5
Goldberg, A. M., Bakhireva, L. N., Page, K., & Henrie, A. M. (2022) · Epidemiologic Reviews · doi:10.1093/epirev/mxac009 · Cited by 5
Khan, A. H., Nolan, B., Stavniichuk, A., Merk, D., & Imig, J. D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1269261 · Cited by 5
Catalá-López, F., Saint-Gerons, D. M., Honrubia, C. D. L. F., & Martín-Serrano, G. (2014) · Revista Española de Salud Pública · doi:10.4321/s1135-57272014000100004 · Cited by 5
Du, N., Liu, S., Cui, C., Zhang, M., Jia, J., & Cao, X. (2016) · Renal Failure · doi:10.1080/0886022x.2016.1256319 · Cited by 5
Henrie, A. M., Sather, M. R., Bakhireva, L. N., Nawarskas, J. J., Boardman, K. D., & Huang, G. D. (2018) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2018.100313 · Cited by 5
Chronische Niereninsuffizienz: Was ist gesichert in der Therapie?
Fleig, S. V., Patecki, M., & Schmitt, R. (2016) · Der Internist · doi:10.1007/s00108-016-0150-7 · Cited by 5
Musetti, C., Quaglia, M., & Stratta, P. (2014) · Kidney International · doi:10.1038/ki.2014.42 · Cited by 5
Cellular, Molecular and Therapeutic Advances in Type 2 Diabetes Mellitus
Potdar, P. D., & Chaudhari, M. B. (2016) · Diabetes Management · Cited by 5
Comprehensive management of chronic kidney disease in the old population
Franco, M. E. P., Puente-García, A., Perez-Belmonte, L. M., Pérez, N., Ellingson, S., & Tornero, F. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2551217 · Cited by 5
Zhang, R., Lan, X., Wu, C., Wang, J., Yin, C., Wang, L., Liu, P., & Li, P. (2025) · eFood · doi:10.1002/efd2.70100 · Cited by 5
A comprehensive review on indigenous therapeutic approaches in kidney care using Ayush medicine
Niharika, Parveen, R., Parveen, B., Umar, S., & Ahmad, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1588424 · Cited by 4
Current Landscape and Emerging Therapeutic Targets in Diabetic Kidney Disease
Hu, S., Lee, K., He, C., & Fan, Y. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001053 · Cited by 5
Ristić, P., Srejovic, I. M., Nikolic, T. R., Milosavljevic, I. M., Ristić, D., Zivkovic, V. I., & Jakovljevic, V. L. (2016) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-016-2890-z · Cited by 6
Wang, S., Djama, N. M., Lai, Y., Li, H., Liao, W., Liao, Y., & Bin, J. (2019) · Journal of Clinical Hypertension · doi:10.1111/jch.13471 · Cited by 4
Metadata
- Authors
- Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., Reilly, R. F., Seliger, S. L., Warren, S. R., Watnick, S., Peduzzi, P., & Guarino, P.
- Affiliations
- Boston University (US)
- Loyola University Medical Center (US)
- VA Connecticut Healthcare System (US)
- University of New Mexico (US)
- University of Arizona (US)
- Ascension (US)
- University of Pittsburgh (US)
- VA North Texas Health Care System (US)
- University of Maryland, Baltimore (US)
- Portland VA Medical Center (US)
- Yale University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-11-14
- Volume
- 369
- Issue
- 20
- Pages
- 1892-1903
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2162368776
- Semantic Scholar
- 7e191f2ee9fe17b31623d78bf58b03d157e94654
- Cited by
- 1,169
- References
- 19
- Citations by year
- 2026: 32 · 2025: 56 · 2024: 67 · 2023: 95 · 2022: 75 · 2021: 102 · 2020: 89 · 2019: 105 · 2018: 88 · 2017: 98 · 2016: 104 · 2015: 123 · 2014: 122 · 2013: 9
- FWCI
- 90.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- diabetic nephropathy, losartan, lisinopril, ACE inhibitors, angiotensin receptor blockers, type 2 diabetes, estimated glomerular filtration rate decline, end-stage renal disease, albuminuria, hyperkalemia, acute kidney injury, drug safety, early trial termination, cardiovascular events, mortality, proteinuria, kidney disease progression
- MeSH terms
- Adult, Angiotensin-Converting Enzyme Inhibitors, Diabetic Nephropathies, Double-Blind Method, Drug Therapy, Combination, Female, Glomerular Filtration Rate, Humans, Kidney Failure, Chronic, Male, Middle Aged, Lisinopril, Losartan, Angiotensin II Type 1 Receptor Blockers, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.